Rivaroxaban for acute DVT

>
By  |  December 5, 2010 | 

In this large randomized trial of patients with acute DVT, rivaroxaban (oral Xa inhibitor) was non-inferior to lovenox (bridged to coumadin) in the primary outcome of recurrent DVT, with the same incidence of bleeding. After 6-12 months of treatment, those that continued on rivaroxaban had significantly fewer recurrent DVTs than those that continued on placebo. Rivaroxaban is non-inferior to lovenox/warfarin for acute DVT, and better than placebo for ongoing longer term treatment (abstract). It is not currently FDA approved in the US but is under review.

Share This Post

Leave A Comment

For security, use of Google's reCAPTCHA service is required which is subject to the Google Privacy Policy and Terms of Use.

About the Author: Danielle Scheurer

Danielle Scheurer, MD, MSCR, SFHM is a clinical hospitalist and the Chief Quality Officer at the Medical University of South Carolina in Charleston, South Carolina, where she also serves as Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She is also the President of SHM's Board of Directors and previously served as Physician Editor of The Hospitalist, SHM's monthly newsmagazine.

Categories

Related Posts

July 2, 2015 |  0
I am coming up on my two year anniversary. Not my wedding anniversary (soon to be 15 years – thanks Maia!), but two years since I joined the ranks of the patients. It was two years ago this week that my day was interrupted by a page from my internist saying, “I don’t know how […]
September 8, 2014 |  3
  As you can see, no glamour shots for this month’s post. I knew it would come at some point, and my first hospitalization related to my CLL came in a big way in mid-July. Given my interest in global health, it was only fitting that I managed to get sick while out of the […]
July 6, 2013 |  0
This large multicenter trial randomized patients with acute VTE to apixaban (10mg BID for 1 week, followed by 5mg BID for 6 months) versus conventional therapy (lovenox-warfarin). The primary outcome was similar between groups (symptomatic VTE or death related to VTE), but major and minor bleeding occurred significantly less often with apixaban. Apixaban is a […]
Go to Top